[Skip to Content]
[Skip to Content Landing]
Views 153
Citations 0
Comment & Response
July 27, 2020

Integrated Drug Reviews at the US Food and Drug Administration—Reply

Author Affiliations
  • 1Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore
  • 2Engelberg Center on Innovation Law & Policy, New York University School of Law, New York, New York
  • 3Health Law Institute, Schulich School of Law, Dalhousie University, Halifax, Nova Scotia, Canada
  • 4Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
JAMA Intern Med. Published online July 27, 2020. doi:10.1001/jamainternmed.2020.1978

In Reply We thank Woodcock et al for their response to our Viewpoint.1 We recognize the challenges of conveying the right level of information to multiple audiences, including clinicians, patients, and researchers. Nevertheless, the Letter does not resolve the “misconceptions” it claims underlie our Viewpoint, and we still have concerns about integrated drug reviews at the US Food and Drug Administration (FDA).

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×